Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway

Insights into the oncogenic effects of /PIK3CA/ mutations from the structure of p110α/p85α

(2011) Chuan-Hsiang Huang et al.   CELL CYCLE

Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma

(2010) Donna E. Hansel et al.   AMERICAN JOURNAL OF PATHOLOGY

Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy

(2010) Xuerong Wang et al.   CANCER BIOLOGY & THERAPY

Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway byNanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma

(2010) Diana Cirstea et al.   MOLECULAR CANCER THERAPEUTICS

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

A complex interplay between Akt, TSC2 and the two mTOR complexes: Figure 1

(2009) Jingxiang Huang et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer

(2009) Margaret A. Knowles et al.   CANCER AND METASTASIS REVIEWS

Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer

(2009) C. M. Seager et al.   Cancer Prevention Research

Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin

(2009) D. Liu et al.   CANCER RESEARCH

Activation of the PI3K/AKT Pathway Induces Urothelial Carcinoma of the Renal Pelvis: Identification in Human Tumors and Confirmation in Animal Models

(2009) C.-N. Qian et al.   CANCER RESEARCH

Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk

(2009) Meng Chen et al.   CARCINOGENESIS

Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer

(2009) F. M. Platt et al.   CLINICAL CANCER RESEARCH

PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?

(2009) Peng Wu et al.   CURRENT MEDICINAL CHEMISTRY

Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors

(2009) Dexin Kong et al.   CURRENT MEDICINAL CHEMISTRY

Current Perspectives on Akt Akt-ivation and Akt-ions

(2009) Ronald W. Matheny et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Targeting the mTOR pathway using deforolimus in cancer therapy

(2009) Devalingam Mahalingam et al.   Future Oncology

Inactivation of p53 and Pten promotes invasive bladder cancer

(2009) A. M. Puzio-Kuter et al.   GENES & DEVELOPMENT

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model

(2009) Ruifang Mi et al.   Journal of Genetics and Genomics

New insights into the role of the tuberous sclerosis genes in leukemia

(2009) Margit Rosner et al.   LEUKEMIA RESEARCH

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K

(2009) J M Askham et al.   ONCOGENE

The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis

(2009) D. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

(2008) C Le Tourneau et al.   BRITISH JOURNAL OF CANCER

UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers

(2008) Sun-Young Kong et al.   CANCER SCIENCE

Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment

(2008) Bing-Hua Jiang et al.   DRUG RESISTANCE UPDATES

Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells

(2008) Isaya Hashimoto et al.   EUROPEAN JOURNAL OF CANCER

Akt as a therapeutic target in cancer

(2008) Linda S Steelman et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms

(2008) Louis S. Pymar et al.   HUMAN MOLECULAR GENETICS

ATP modulates PTEN subcellular localization in multiple cancer cell lines

(2008) Glenn P. Lobo et al.   HUMAN MOLECULAR GENETICS

Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells

(2008) Shigeru Kanda et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Cotargeting survival signaling pathways in cancer

(2008) Steven Grant   JOURNAL OF CLINICAL INVESTIGATION

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia

(2008) L S Steelman et al.   LEUKEMIA

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies: Figure 1.

(2008) Jorge A. Garcia et al.   MOLECULAR CANCER THERAPEUTICS

Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray

(2008) Loleta D. Harris et al.   MOLECULAR CARCINOGENESIS

Class I PI3K in oncogenic cellular transformation

(2008) L Zhao et al.   ONCOGENE